Florida Biologix®, headquartered in Alachua, Fla., is a preclinical and early clinical biologics contract development, manufacturing, and testing organization focused on a wide range of value-optimizing services, including: cell line engineering, cGMP cell banking, process development, assay development, cGMP vector/protein production in mammalian and insect cells, fill and finish of parenteral formulations, product testing, and regulatory support.

Florida Biologix was established in 2006 as a component of the University of Florida Center of Excellence for Regenerative Health Biotechnology with a mission to provide drug-development services to the biotechnology industry.  The State of Florida, the University of Florida, and the U.S. Department of Commerce Economic Development Administration provided the center with seed funding as part of Florida's effort to grow its biotechnology industry. It spun out of the university and went private in November 2015 with an investment from Ampersand Capital Partners.

In March 2016, Florida Biologix merged with a Massachusetts-based biotechnology company to form Brammer Bio, which provides a full range of viral vector process and analytical development, clinical and commercial manufacturing and supply services to cell and gene therapy companies.

In May 2019, Thermo Fisher Scientific completed the acquisition of Brammer Bio to form the new Viral Vector Services (VVS) business within its Pharma Services Group. Thermo Fisher’s VVS business is a leading viral vector CDMO, continuing Brammer Bio’s mission of enabling biopharma customers to deliver breakthrough medicines to patients by unleashing the potential of gene therapies and gene-modified cell therapies.


For more information, please visit Brammer Bio at www.BrammerBio.com